Advertisement

ASCO GI 2023: NAPOLI-3 Trial in Metastatic Pancreatic Ductal Adenocarcinoma
Posted: 02/08/2023 | By: Sarah Campen, PharmD

At the 2023 ASCO Gastrointestinal Cancers Symposium, Wainberg et al presented results from NAPOLI-3, a randomized, open-label, phase III study investigating the efficacy and safety of NALIRIFOX compared with nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic cancer (Abstract LBA661).

Question 1 of 5

The treatment regimen NALIRIFOX includes:

Choose 1

A
Gemcitabine at 1,000 mg/m2, capecitabine at 1,200 mg/m2, leucovorin at 400 mg/m2, and oxaliplatin at 60 mg/m2
B
Liposomal irinotecan at 50 mg/m2, 5-fluorouracil at 2,400 mg/m2, leucovorin at 400 mg/m2, and oxaliplatin at 60 mg/m2
C
Liposomal irinotecan at 50 mg/m2, 5-fluorouracil at 2,400 mg/m2, leucovorin at 400 mg/m2, and cisplatin at 50 mg/m2
D
Liposomal irinotecan at 5 mg/m2, 5-fluorouracil at 240 mg/m2, leucovorin at 40 mg/m2, and oxaliplatin at 60 mg/m2

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage